Drug Profile
RQ 00310941
Alternative Names: 5-HT 2B antagonist - RaQualiaLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer Japan
- Developer RaQualia Pharma
- Class Amides; Anti-inflammatories; Irritable bowel syndrome therapies; Morpholines; Pyrazoles; Quinolines; Small molecules
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Irritable bowel syndrome
- No development reported Inflammatory bowel diseases
Most Recent Events
- 17 Apr 2024 RQ 00310941 is still in phase I trials for Irritable-bowel-syndrome in United Kingdom
- 28 Nov 2023 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases in Japan
- 28 Nov 2023 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome(In volunteers) in United Kingdom